Tricida to Report Third Quarter Financial Results and Host Conference Call and Webcast on Thursday, November 14, 2019

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its third quarter 2019 financial results after the close of market on Thursday, November 14, 2019. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its financial results and business progress. The call or webcast may be accessed as follows:

A replay of the webcast will be available on Tricida’s website approximately two hours following the completion of the call and will be available for up to 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States. Tricida has submitted a New Drug Application seeking approval of veverimer through the U.S. Food and Drug Administration’s Accelerated Approval Program, and is currently conducting its confirmatory postmarketing trial, VALOR-CKD.

For more information about Tricida, please visit Tricida.com.

Contacts

Jackie Cossmon, IRC

Tricida, Inc.

Vice President of Investor Relations and Communications

[email protected]